

Cyclin Dependent Kinase 4 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/CCF2143A7ECCEN.html>

Date: January 2020

Pages: 169

Price: US\$ 3,500.00 (Single User License)

ID: CCF2143A7ECCEN

Abstracts

Cyclin Dependent Kinase 4 - Pipeline Review, H1 2020

SUMMARY

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 32 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 4 - Pipeline Review, H1 2020, outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.

The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 4, 7, 3, 8 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Metabolic Disorders and Toxicology which include indications Breast Cancer, Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Metastatic Colorectal Cancer, Acute Lymphocytic

Leukemia (ALL, Acute Lymphoblastic Leukemia), Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Hepatocellular Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Bladder Cancer, Colon Cancer, Dedifferentiated Liposarcoma, Epithelial Ovarian Cancer, Esophageal Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leukemia, Liposarcoma, Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Neuroblastoma, Neuroendocrine Tumors, Oligodendroglioma, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Thymic Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, AIDS - Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Brain Tumor, Cervical Cancer, Chemotherapy Induced Myelosuppression, Chordoma, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Ductal Carcinoma In Situ, Duodenal Cancer, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, High-Grade Glioma, Hormone Sensitive Breast Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Cancer (Renal Cell Cancer), Lung Cancer, Malignant Mesothelioma, Marginal Zone B-cell Lymphoma, Medulloblastoma, Melanoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Nonmelanomatous Skin Cancer, Primary CNS Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Thymoma (Thymic Epithelial Tumor), Transitional Cell Cancer (Urothelial Cell Cancer), Type 2 Diabetes and Well Differentiated Liposarcoma.

Furthermore, this report also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)

The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects

The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development

Beta Pharma Inc

Betta Pharmaceuticals Co Ltd

CStone Pharmaceuticals Co Ltd

Eli Lilly and Co

ESSA Pharma Inc

Fochon Pharmaceutical Ltd

G1 Therapeutics Inc

Guangzhou BeBetter Medicine Technology Co Ltd

HEC Pharm Co Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Rizen (Suzhou) Biosciences Co Ltd

Shanghai Haihe Biopharma Co Ltd

Shanghai Haishi Biopharmaceutical Co Ltd

Shanghai Pharmaceutical Group Co Ltd

SignalRx Pharmaceuticals Inc

Sihuan Pharmaceutical Holdings Group Ltd

Sino Biopharmaceutical Ltd

Tetranov International Inc

Tiziana Life Sciences Plc

ViroStatics SRL

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Drug Profiles

abemaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BEBT-209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-1178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-16350 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-3002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit CDK4 for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FCN-437c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-381 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HEC-80797 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HS-10342 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JS-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ierociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-108110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-123300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06873600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ribociclib succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-6390 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4/6 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target AR, CDK4 and CDK6 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TQ-05510 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
trilaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voruciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS.-2370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-3287 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1)

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Beta Pharma Inc, H1 2020

Pipeline by Betta Pharmaceuticals Co Ltd, H1 2020

Pipeline by CStone Pharmaceuticals Co Ltd, H1 2020

Pipeline by Eli Lilly and Co, H1 2020

Pipeline by ESSA Pharma Inc, H1 2020

Pipeline by Fochon Pharmaceutical Ltd, H1 2020

Pipeline by G1 Therapeutics Inc, H1 2020

Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, H1 2020

Pipeline by HEC Pharm Co Ltd, H1 2020

Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2020

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020

Pipeline by MEI Pharma Inc, H1 2020

Pipeline by Novartis AG, H1 2020

Pipeline by Onconova Therapeutics Inc, H1 2020

Pipeline by Pfizer Inc, H1 2020

Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H1 2020

Pipeline by Shanghai Haihe Biopharma Co Ltd, H1 2020

Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, H1 2020

Pipeline by Shanghai Pharmaceutical Group Co Ltd, H1 2020

Pipeline by SignalRx Pharmaceuticals Inc, H1 2020

Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H1 2020

Pipeline by Sino Biopharmaceutical Ltd, H1 2020

Pipeline by Tetranov International Inc, H1 2020

Pipeline by Tiziana Life Sciences Plc, H1 2020

Pipeline by ViroStatics SRL, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Dormant Products, H1 2020 (Contd..2), H1 2020

Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

COMPANIES MENTIONED

Beta Pharma Inc

Betta Pharmaceuticals Co Ltd

CStone Pharmaceuticals Co Ltd

Eli Lilly and Co

ESSA Pharma Inc

Fochon Pharmaceutical Ltd

G1 Therapeutics Inc

Guangzhou BeBetter Medicine Technology Co Ltd

HEC Pharm Co Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Rizen (Suzhou) Biosciences Co Ltd

Shanghai Haihe Biopharma Co Ltd

Shanghai Haishi Biopharmaceutical Co Ltd

Shanghai Pharmaceutical Group Co Ltd

SignalRx Pharmaceuticals Inc

Sihuan Pharmaceutical Holdings Group Ltd

Sino Biopharmaceutical Ltd

Tetranov International Inc

Tiziana Life Sciences Plc

ViroStatics SRL

I would like to order

Product name: Cyclin Dependent Kinase 4 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/CCF2143A7ECCEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCF2143A7ECCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970